Alkem Laboratories Ltd. Share Price

Alkem Labs initiates forensic audit on fund misappropriation

Alkem Laboratories Limited (ALKEM) has approved the initiation of a forensic audit. The Audit Committee approved the move on 21 October 2026 in connection with alleged misappropriation of funds by a former employee. The forensic audit has been initiated to examine the facts and circumstances relating to the incident. It will determine the root cause of the incident and recommend appropriate corrective measures. The disclosure was made under Regulation 30 of SEBI (LODR) Regulations. The key trigger is the initiation of a forensic audit into alleged misappropriation of funds by a former employee, which highlights internal control and governance aspects. While the quantum and materiality are not yet known, such announcements can create near-term uncertainty. Peers in the pharmaceutical space such as Sun Pharmaceutical, Cipla, and Lupin may face comparison on governance standards and internal controls. Near-term prices could see a negative reaction until clarity emerges on the financial impact and findings. Risks include any material financial loss, regulatory scrutiny, or delays in completing the audit. Competitors listed: Sun Pharmaceutical, Cipla, Lupin.

See More

Alkem breaks below range support as averages turn lower

Alkem Laboratories has broken below the lower edge of its recent consolidation range, closing near ₹4,984 after slipping beneath the ₹5,087–₹5,170 support band. The breakdown matters because this zone had repeatedly contained price during the past few months. The stock is now below all three visible moving averages: the 20-day EMA near ₹5,184.8, the 50-day EMA around ₹5,277.3, and the 200-day EMA near ₹5,382.6.

That alignment places resistance overhead in layers. A recovery above ₹5,087 would be the first attempt to repair the breakdown, but ₹5,185 is the short-term confirmation level. Beyond that, ₹5,277–₹5,383 is the larger supply zone created by the 50-day and 200-day averages. Unless price can regain those levels, rebounds are more likely to be corrective than the start of a new uptrend. The immediate downside reference is ₹4,900–₹4,950. If this area fails, ₹4,800 is the next visible level, while the broad long-term support zone near ₹4,100 becomes relevant only in a deeper decline. Alkem’s domestic formulations and export exposure give the business defensive characteristics, but the chart is currently demanding proof from buyers. The key signal is whether ₹5,087 can be reclaimed promptly; failure to do so keeps the breakdown in control and leaves lower supports vulnerable.

See More

buy on dips to follow due to correction in market

Alkem Laboratories Limited is an Indian pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products. Its business includes domestic formulations, branded generics and international pharmaceutical markets. 2. Latest Share Price and Market Performance As of 9 October 2026, Alkem Laboratories was trading at approximately ₹5,279 per share. Its previous closing price was around ₹5,241. The stock's reported 52-week high was ₹5,933, while its 52-week low was ₹5,052. These figures indicate that the stock remains below its recent peak and is trading relatively close to the lower end of its 52-week range. 3. Fundamental Analysis and Latest Financial Results Alkem Laboratories reported consolidated revenue of approximately ₹3,740 crore for Q1 FY2026–27, representing year-on-year growth of 10.95%. Operating profit was around ₹766 crore, while net profit stood at approximately ₹521 crore. Although revenue growth was encouraging, net profit declined by about 22% year-on-year, highlighting the importance of monitoring costs, margins and exceptional items. NSE 5,175.00, BSE 5,132.55 Tese factors suggest that revenue momentum remains constructive, but sustained earnings growth will be important to justify the stock's valuation. Positive scenario: Revenue growth remains healthy, domestic formulations perform well, margins stabilise and the stock moves above resistance with strong volume. This combination could support a recovery towards higher price levels. Negative scenario: API costs increase, profit growth remains weak or the stock breaks below its recent support area. In this situation, the possibility of further downside should be considered. Neutral scenario: The stock continues moving sideways while the market waits for stronger evidence of earnings improvement. Investors may prefer to wait for confirmation rather than make decisions based on short-term price fluctuations.

See More

ALKEM LABORATORIES SHARES SLIP AFTER CFO RESIGNS

Shares of Alkem Laboratories came under pressure in afternoon trade on Thursday after the pharmaceutical company announced the resignation of its Chief Financial Officer and Key Managerial Personnel, Nitin Agrawal. In an exchange filing dated September 24, the company said Agrawal had submitted his resignation on July 30, 2026, to pursue new professional opportunities. He will step down as CFO and cease to be a Senior Management Personnel of Alkem Laboratories with effect from September 30, 2026. In his resignation letter, Agrawal described his tenure as CFO of Alkem Laboratories as a "great honour" and said he would look back on his time with the company with gratitude. Agrawal highlighted several strategic initiatives he was involved in during his tenure, including building the company’s MedTech business from the ground up, the acquisition of Adroit, the creation of Alkem Wellness, the formation of a joint venture in Saudi Arabia and the acquisition of Bombay Ortho. He also said he had supported the monetisation of idle assets, including the Indore SEZ plant, improved returns from treasury income and helped implement the new UCPMP marketing guidelines in the domestic market. More recently, he was involved in leading the acquisition of Oculotech. Explaining his decision to step down, Agrawal said the move had not been easy but that he had chosen to pursue professional opportunities that were more closely aligned with his long-term professional and personal growth.

See More

Alkem Laboratories Shares Slip Over 2% After CFO Steps Down

Alkem Laboratories declined more than 2% in Thursday afternoon trade after the pharmaceutical company announced the resignation of its Chief Financial Officer and Key Managerial Personnel, Nitin Agrawal. The stock dropped as much as 2.04%, or ₹110.50, to ₹5,307 on the NSE around 12:44 pm. By 12:53 pm, it was trading at ₹5,318, down 1.84%. In an exchange filing on September 24, Alkem stated that Agrawal had resigned on July 30, 2026, to pursue new professional opportunities. He will remain in his role until September 30, 2026, to ensure a smooth transition. In his resignation letter, Agrawal described his tenure as “a great honour” and expressed gratitude for the experience. He thanked the board for entrusting him with key strategic initiatives, including building the MedTech business, acquiring Adroit, creating Alkem Wellness, forming a Saudi joint venture, and acquiring Bombay Ortho and Oculotech.

See More

Alkem rebounds from support, but cloud still caps it

has bounced sharply from the ₹5,100 to ₹5,160 support band, with price recovering to around ₹5,348. The rebound is notable because that lower zone has acted as support before, but the stock is still trading below a heavy Ichimoku resistance cluster. The business itself remains anchored in domestic branded formulations, chronic therapies and a meaningful US presence. That gives Alkem a relatively defensive earnings profile, but the chart is still in a transition phase rather than a clean uptrend. The Tenkan sits near ₹5,206, while the Kijun is around ₹5,293. Price has moved above both, which is the first positive sign. The bigger hurdle is the cloud, with resistance stretching roughly from ₹5,250 to ₹5,470 and a visible supply zone around ₹5,550 to ₹5,600. My reading is that the bounce has improved the setup, but confirmation is still missing. A sustained move above ₹5,470 would strengthen the case for a larger recovery toward ₹5,550 to ₹5,600. If the stock slips back below ₹5,200, the recent rebound would start to look like another failed attempt. For now, this is a recovery setup, not a confirmed breakout.

See More